

Date:14thJune, 2021

To,
The Secretary,
BOMBAY STOCK EXCHANGE LIMITED,
1st Floor, New Trading Ring
Rotunda Building, P.J.Towers,
Dalal Street,
Mumbai-400001.

Scrip Code:524564

Dear Sir,

Sub: Intimation under Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding outcome of Board Meeting

In compliance with Regulation 33 & 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results for the Fourth Quarter and Financial Year ended 31stMarch 2021 which have been reviewed by the Audit Committee and approved by the Board at their meetings held today i.e., 14thJune 2021 and also the Audit Report furnished by the Statutory Auditors of the Company.

We are also forwarding herewith the Declaration of unmodified opinion with Audit Report and press release being issued in this connection and also

The meeting of the Board of Directors of the Company commenced at 2.30 PM and concluded at 4.40 p.m.

We would request you to please take note of the same.

Thanking you sir,

For GAYATRI BIOORGANICS LIMITED


C.V. Rayudu
C.V Rayudu
Wholetime Director



STATEMENT OF AUDITED FINANCIALS RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(□ in Lakhs unless otherwise stated)

Sr.	Particulars	Quarter Ended		Year ended	
		March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020
		(Refer Note 4)	(Refer Note 4)	(Audited)	(Audited)
	Continuing Operations				
1	Revenue from operations (Refer Note 5)	-	-	-	-
2	Other Income	-	0.30	-	6.37
3	Total Revenue from operations (1+2)	-	0.30	-	6.37
4	Expenses (Refer Note 5)				
	Cost of Materials Consumed	-	-	-	-
	Changes in Inventories of Finished Goods and Work in Progress	-	-	-	-
	Employee Benefits Expenses	7.12	7.23	28.48	28.07
	Finance Cost	0.07	0.58	0.10	0.58
	Depreciation and Amortisation Expenses	-	-	-	-
	Other Expenses (Including Excise expense)	7.55	5.06	21.15	32.85
	Total Expenses	14.75	12.88	49.74	61.50
5	Profit/(Loss) before exceptional and extraordinary items and tax (3-4)	(14.75)	(12.58)	(49.74)	(55.13)
6	Add/(Less): Exceptional Items	-	-	-	-
7	Profit / (loss) before tax for the period / year (5-6)	(14.75)	(12.58)	(49.74)	(55.13)
8	Tax Expense	-	(12.41)	-	-
9	Profit/(Loss) from continuing operations for the period / year (7-8)	(14.75)	(0.16)	(49.74)	(55.13)
	Discontinuing Operations				
10	Profit/(Loss) from discontinuing operations (Refer Note 5)	-	-	-	-
	Add/(Less): Exceptional Items (Refer Note 5)	-	(9.31)	-	8,502.15
11	Tax expense of discontinuing operations (Refer Note 5)	-	-	-	-
12	Profit / (Loss) from discontinuing operations after tax for the period / year (10-11)	-	(9.31)	-	8,502.15
13	Net Profit/(Loss) for the period / year (9+12)	(14.75)	(9.48)	(49.74)	8,447.01
	Discontinuing Operations				
14	Other Comprehensive Income (net of Tax)				
	Items that will not be reclassified to Statement of Profit and Loss				
	(a) Remeasurement of employee benefit obligation	-	-	-	-
	(b) Income tax relating to above item	-	-	-	-
15	Total Comprehensive Income/(Loss) for the period / year (After tax) (13+14)	(14.75)	(9.48)	(49.74)	8,447.01
16	Paid-up Equity Share Capital	7,878.81	7,878.81	7,878.81	7,878.81
17	Other Equity	-	-	(11,176.70)	(11,126.96)
18	Earnings per share in □ for discontinued operations (annualised except for quarter)				
	Basic	(0.02)	(0.01)	(0.06)	10.72
	Diluted	(0.02)	(0.01)	(0.06)	10.72
	(see accompanying notes to the financial results)				



Regd. & Corp. Office

Gayatri Bioorganics Limited, B1, 1st Floor, 6-3-1090. TSR Towers
Raj Bhavan Road, Somajiguda, Hyderabad 500 082. Telangana

CIN NO : L24110TG1991PLC013512

T +91 40 6610 0111 / 6610 0222

F +91 40 6610 0333

E info@gayatribioorganics.com
gayatribioorganics@gmail.com
www.gayatribioorganics.com

NOTES

- 1 The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meeting held on Jun 14, 2021.
- 2 The above financial results are extracted from the Audited Financial Statements of the Company, which are prepared in accordance with Indian Accounting Standards ('Ind AS') as prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder.
- 3 With effect from April 1, 2018, the Company has adopted Ind AS 115 – "Revenue from contracts with customers" under the full retrospective approach. Accordingly, the comparatives have been adjusted to give the effect of Ind AS 115. The effect on adoption of Ind AS 115 was insignificant on the financial results.
- 4 The figures for the quarter ended March 31, 2021 and March 31, 2020 are balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2020 respectively.
- 5 The financial statements have been prepared on a going concern basis based upon Comfort letter given by the promoters of the Company for any other business to be continued by them in the future.
- 6 The Company doesn't have more than one segment. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 7 The figures for the corresponding previous period have been regrouped/reclassified/restated wherever necessary to make them comparable with the current year's classification.

**By order of the Board
For Gayatri Bioorganics Limited**

T. Sandeep Kumar Reddy
Chairman
DIN: 00005573



Place: Hyderabad
Date: Jun 14, 2021

Regd. & Corp. Office

Gayatri Bioorganics Limited, B1, 1st Floor, 6-3-1090, TSR Towers
Raj Bhavan Road, Somajiguda, Hyderabad 500 082, Telangana

CIN NO : L24110TG1991PLC013512

T +91 40 6610 0111 / 6610 0222
F +91 40 6610 0333

E info@gayatribioorganics.com
gayatribioorganics@gmail.com
www.gayatribioorganics.com

**GAYATRI****STATEMENT OF ASSETS AND LIABILITIES**

(□ In Lakhs)

Sr. No.	Particulars	As at March 31 2021 (Audited)	As at March 31 2020 (Audited)
I.	ASSETS		
1	Non-Current Assets		
	(a) Financial assets		
	(i) Investments	0.15	0.15
	(ii) Other Financial Assets	9.06	8.88
	(b) Other Non Current Assets	-	-
		9.21	9.03
2	Current Assets		
	(a) Financial Assets		
	(i) Trade Receivables	48.46	48.46
	(ii) Cash and Cash equivalents	43.76	95.60
	(iii) Other Financial Assets	11.97	11.97
	(b) Other Current assets	145.97	144.31
		250.15	300.33
3	Assets held for sale (Refer note 5)	-	-
	TOTAL ASSETS	259.36	309.37
	EQUITIES AND LIABILITIES		
1	EQUITY		
	(a) Equity Share Capital	7,878.81	7,878.81
	(b) Other Equity	(11,176.70)	(11,126.96)
		(3,297.89)	(3,248.14)
	LIABILITIES		
2	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	170.16	170.16
		170.16	170.16
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	3,340.35	3,340.35
	(ii) Trade Payables	44.19	44.58
	(b) Other Current liabilities	2.54	2.42
		3,387.08	3,387.35
4	Liabilities held for sale (Refer note 5)	-	-
	TOTAL EQUITY AND LIABILITIES	259.36	309.37

Regd. & Corp. Office

Gayatri Bioorganics Limited, B1, 1st Floor, 6-3-1090, TSR Towers
Raj Bhavan Road, Somajiguda, Hyderabad 500 082, Telangana**CIN NO : L24110TG1991PLC013512**T +91 40 6610 0111 / 6610 0222
F +91 40 6610 0333E info@gayatribioorganics.com
gayatribioorganics@gmail.com
www.gayatribioorganics.com



(□ in lakhs unless otherwise stated)

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020
A. Cash Flow from Operating Activities		
(Loss) before tax	(49.74)	8,447.01
Adjustments for:		
- Depreciation and Amortization	-	-
- Finance Costs	0.10	0.58
Operating Profit Before Working Capital Changes	(49.64)	8,447.59
Changes in operating assets and liabilities:		
(Increase) / Decrease in Operating Assets:		
- Non-current Financial Assets & Other Assets	(0.18)	-
- Trade Receivables	-	3.96
- Changes For Assets Held For Sale	-	-
- Current Financial Assets	-	0.81
- Other current assets	(1.66)	(7.57)
Increase / (Decrease) in Operating Liabilities:		
- Trade Payables	(0.39)	11.61
- Changes For Liabilities Held For Sale	-	-
- Other Current Liabilities	0.12	2.42
Cash (used in) / generated from Operations	(51.74)	8,458.82
Net cash (used in) Operating Activities (A)	(51.74)	8,458.82
B. Cash Flow from Investing Activities		
- Capital expenditure on Property, Plant and Equipment, including capital advances	-	-
- Interest Received/ Reversed for Wrong Entry	-	-
Net cash flow (used in) investing activities (B)	-	-
C. Cash Flow from Financing Activities		
- Interest and Finance Charges paid	(0.10)	(0.58)
Net cash flow from financing activities (C)	(0.10)	(0.58)
Net increase / (decrease) in cash and cash equivalents (A + B + C)	(51.84)	8,458.24
Cashflow from discontinued operations	-	(8,385.64)
Cash and Cash Equivalents at the beginning of year	95.60	23.00
Cash and Cash Equivalents at the end of year (Refer Note - 2.3(b) & 2.5)	43.76	95.60

The notes referred to above form an integral part of the financial statements

As per our report attached

For N G RAO & ASSOCIATES
Chartered Accountants

G Nageswara Rao
Partner

Place: Hyderabad
Date: Jun 14, 2021



For Gayatri BioOrganics Limited

T. Sandeep Kumar Reddy
Chairman
DIN : 00005573

C V Rayudu
Director
DIN : 03536579

Place: Hyderabad
Date: Jun 14, 2021



Independent Auditor's Review Report on the Quarterly and year to date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To
The Board of Directors
M/s. Gayatri Bioorganics Limited.**

We have reviewed the accompanying statement of unaudited financial results of M/s. Gayatri Bioorganics Limited ("the Company") for the Quarter ended 31st March 2021 and ("the statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Rao & Associates
Chartered Accountants
FRN: 009399S



(CA G. Nageswara Rao)
Partner
Membership No.207300

Place of Signature: Hyderabad
Date: 14.06.2021
UDIN: 21207300AAABGQ4565

Declaration

Pursuant to Regulation 33(3)(d) of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27th May 2016, we, GAYATRI BIOORGANICS LIMITED, do hereby state and declare that the Statutory Auditors' Reports on the Financial Statements for the Financial Year ended 31st March 2021 are with unmodified opinion.

For GAYATRI BIOORGANICS LIMITED



C.V. Rayudu

C.V. Rayudu
Whole Time Director

Date: 14th June 2021

Place: Hyderabad

PRESS RELEASE



GAYATRI

GAYATRI BIOORGANICS LIMITED

Registered office: B3, Third floor, 6-3-1090, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad - 500 082
Website: www.gayatribioorganics.com, CIN: L24110TG1991PLC013512

Extract of Audited Financial Results for the Year ended March 31, 2021


PARTICULARS	For the Quarter ended 31-03-2021	For Nine Months ended 31-12-2020	For the Quarter ended 31-03-2020
Total income from operations (net)	-	-	0.30
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(14.75)	34.99	12.88
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(14.75)	(34.99)	(9.48)
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(14.75)	(34.99)	(9.48)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(14.75)	(34.99)	(9.48)
Equity Share Capital	7,878.81	7,878.81	7,878.81
Earning Per Share (of Rs. 10/- each) (for continuing and discontinued operations) - - Basic and Diluted	(0.02)	(0.04)	(0.01)

Note:

1. The above is an extract of the detailed format of the Quarterly Financial Results for the Quarter ended March 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Unaudited financials Prepared. The full format of the said quarterly Financial Results is available on the Stock Exchange websites. (www.bseindia.com) and on Company's website: www.gayatribioorganics.com.

By order of the Board of Directors

Hyderabad
June 14, 2021



Regd. & Corp. Office

Gayatri Bioorganics Limited, B1, 1st Floor, 6-3-1090, TSR Towers,
Raj Bhavan Road, Somajiguda, Hyderabad 500 082, Telangana

CIN NO : L24110TG1991PLC013512

T +91 40 6610 0111 / 6610 0222
F +91 40 6610 0333

E info@gayatribioorganics.com
gayatribioorganics@gmail.com
www.gayatribioorganics.com